Yan Ling Selected Research

neurotoxic esterase

1/2021	Reduced neuropathy target esterase in pre-eclampsia suppresses tube formation of HUVECs via dysregulation of phospholipid metabolism.
1/2018	Down-Regulation of Neuropathy Target Esterase in Preeclampsia Placenta Inhibits Human Trophoblast Cell Invasion via Modulating MMP-9 Levels.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yan Ling Research Topics

Disease

19	Neoplasms (Cancer) 03/2024 - 07/2003
7	Inflammation (Inflammations) 12/2023 - 02/2011
6	Tuberculosis (Tuberculoses) 07/2023 - 10/2015
5	Alzheimer Disease (Alzheimer's Disease) 01/2017 - 11/2003
4	Type 2 Diabetes Mellitus (MODY) 01/2020 - 04/2011
4	Sepsis (Septicemia) 03/2015 - 01/2010
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2024 - 01/2022
3	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 08/2011
3	Carcinogenesis 01/2022 - 10/2011
3	Graves Disease (Basedow Disease) 01/2022 - 01/2020
3	Pre-Eclampsia (Preeclampsia) 01/2021 - 01/2018
3	Hepatocellular Carcinoma (Hepatoma) 01/2021 - 01/2018
3	Hypertension (High Blood Pressure) 01/2019 - 01/2017
3	Hypertriglyceridemia 05/2017 - 01/2016
3	Pancreatitis 02/2016 - 07/2008
3	Infections 02/2014 - 06/2012
3	Hyperglycemia 06/2008 - 05/2007
2	Adenocarcinoma of Lung 11/2023 - 07/2021
2	Lymphatic Metastasis 09/2023 - 12/2019
2	Papillary Thyroid Cancer 09/2023 - 01/2018
2	Disease Progression 01/2023 - 01/2020
2	Non-alcoholic Fatty Liver Disease 01/2022 - 01/2018
2	Critical Illness (Critically Ill) 01/2022 - 09/2012
2	Stomach Neoplasms (Stomach Cancer) 01/2022 - 01/2021
2	Neoplasm Metastasis (Metastasis) 03/2020 - 10/2014
2	Atherosclerosis 01/2020 - 08/2007
2	Coronary Artery Disease (Coronary Atherosclerosis) 05/2018 - 01/2017
2	Insulin Resistance 10/2017 - 09/2011
2	Coronary Disease (Coronary Heart Disease) 10/2017 - 05/2017
2	Reperfusion Injury 04/2015 - 10/2012
2	Cognitive Dysfunction 07/2009 - 09/2007
2	Breast Neoplasms (Breast Cancer) 11/2008 - 07/2007
1	Wounds and Injuries (Trauma) 01/2023
1	Residual Neoplasm 01/2023
1	Communicable Diseases (Infectious Diseases) 11/2022
1	Cardiotoxicity 10/2022
1	Body Weight (Weight, Body) 01/2022
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022

Drug/Important Bio-Agent (IBA)

7	Proteins (Proteins, Gene)FDA Link 01/2023 - 11/2003
6	HMGB1 Protein (HMG1)IBA 01/2018 - 07/2008
6	Glucose (Dextrose)FDA LinkGeneric 10/2017 - 08/2007
4	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2019
3	phosphopantetheinyl transferaseIBA 03/2024 - 10/2022
3	EnzymesIBA 07/2023 - 10/2007
3	Immune Checkpoint InhibitorsIBA 01/2023 - 03/2020
3	LipidsIBA 10/2022 - 04/2011
3	ApolipoproteinsIBA 01/2020 - 09/2007
3	oxidized low density lipoproteinIBA 01/2019 - 04/2011
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2019 - 07/2013
3	Triglycerides (Triacylglycerol)IBA 01/2019 - 05/2011
3	Small Interfering RNA (siRNA)IBA 04/2015 - 08/2011
3	Insulin-Like Growth Factor I (IGF-1)IBA 06/2008 - 05/2007
2	Interleukin-6 (Interleukin 6)IBA 12/2023 - 01/2015
2	Tyrosine Kinase InhibitorsIBA 11/2023 - 01/2021
2	ErbB Receptors (EGF Receptor)IBA 11/2023 - 01/2022
2	Thyroid HormonesIBA 09/2023 - 01/2017
2	LactamsIBA 11/2022 - 01/2020
2	AlbuminsIBA 01/2022 - 05/2018
2	neurotoxic esteraseIBA 01/2021 - 01/2018
2	alectinibIBA 01/2021 - 01/2021
2	AldosteroneIBA 01/2020 - 09/2011
2	Blood Glucose (Blood Sugar)IBA 01/2020 - 10/2017
2	Apolipoproteins E (ApoE)IBA 01/2020 - 09/2007
2	HDL CholesterolIBA 01/2019 - 05/2017
2	CytokinesIBA 01/2018 - 01/2015
2	Natalizumab (Tysabri)FDA Link 12/2017 - 06/2017
2	aducanumabIBA 01/2017 - 01/2016
2	Apolipoprotein C-II (ApoC2)IBA 02/2016 - 01/2016
2	Amyloid (Amyloid Fibrils)IBA 01/2016 - 11/2003
2	LigandsIBA 10/2014 - 08/2007
2	Uric Acid (Urate)IBA 11/2013 - 02/2012
1	Thymidylate SynthaseIBA 03/2024
1	raltitrexed (D 1694)IBA 03/2024
1	NF-kappa B (NF-kB)IBA 12/2023
1	Oxidants (Oxidizing Agents)IBA 12/2023
1	AntioxidantsIBA 12/2023
1	osimertinibIBA 11/2023
1	Gefitinib (Iressa)FDA Link 11/2023
1	N-methyladenosineIBA 10/2023
1	Epithelial Cell Adhesion MoleculeIBA 10/2023
1	Cysteine (L-Cysteine)FDA Link 01/2023
1	NanogelsIBA 01/2023
1	CollagenIBA 01/2023
1	anlotinibIBA 01/2023
1	Docetaxel (Taxotere)FDA Link 01/2023
1	HydrogelsIBA 01/2023
1	Angiogenesis InhibitorsIBA 01/2023
1	Cephalosporins (Cephalosporin Antibiotics)IBA 11/2022
1	Ion Channels (Ion Channel)IBA 10/2022
1	benzamideIBA 10/2022
1	Virulence Factors (Pathogenicity Factors)IBA 10/2022
1	tanezumabIBA 01/2022
1	HDL LipoproteinsIBA 01/2022
1	Nerve Growth Factor (NGF)IBA 01/2022
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2022
1	Tumor Biomarkers (Tumor Markers)IBA 07/2021

Therapy/Procedure

13	Therapeutics 04/2024 - 05/2005
4	Immunotherapy 04/2024 - 03/2020
4	Drug Therapy (Chemotherapy) 01/2022 - 10/2007
1	Aftercare (After-Treatment) 11/2023